Literature DB >> 20014459

Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications.

Angel Lanas1, Juan-V Esplugues, Javier Zapardiel, Eduardo Sobreviela.   

Abstract

AIM: To evaluate an evidence-based educational program for improving strategies for prevention of nonsteroidal anti-inflammatory drug (NSAID)-associated gastrointestinal (GI) complications.
METHODS: Four hundred and fifty-six specialists replied to a questionnaire that covered issues related to NSAID-induced adverse effects. They also collected data from their last five consecutive patients before and after they had attended an evidence-based seminar on GI prevention strategies.
RESULTS: Four hundred and forty-one of 456 specialists (96.7%) participated in the survey, and 382 (83.7%) in the education-based study that recorded data from 3728 patients. The specialists overestimated the risk of GI complications with NSAIDs, underestimated the GI safety profile of coxibs, but were aware of the risk factors and of the current prevention strategies. Proton pump inhibitors were co-prescribed with NSAIDs in > 80% of patients with and without risk factors. The educational program had little impact on prescribing habits.
CONCLUSION: Specialists are informed of advances in NSAID-associated adverse effects and have high rates of GI-prevention therapy. Our educational program did not alter these rates.

Entities:  

Keywords:  Adverse effects; Cyclooxygenase 2 inhibitors; Education; Gastrointestinal diseases; Nonsteroidal anti-inflammatory agents; Proton pump inhibitors

Mesh:

Substances:

Year:  2009        PMID: 20014459      PMCID: PMC2795182          DOI: 10.3748/wjg.15.5953

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Summing the risk of NSAID therapy.

Authors:  James M Scheiman; A Mark Fendrick
Journal:  Lancet       Date:  2007-05-12       Impact factor: 79.321

Review 2.  Proton pump inhibitors for gastroduodenal damage related to nonsteroidal anti-inflammatory drugs or aspirin: twelve important questions for clinical practice.

Authors:  Gaurav Arora; Gurkirpal Singh; George Triadafilopoulos
Journal:  Clin Gastroenterol Hepatol       Date:  2009-03-21       Impact factor: 11.382

3.  [Cost stratification of nonsteroidal anti-inflammatory drug-associated gastrointestinal side effects].

Authors:  A Lanas
Journal:  Med Clin (Barc)       Date:  2000       Impact factor: 1.725

4.  Improved use of thromboprophylaxis for deep vein thrombosis following an educational intervention.

Authors:  Steven L Cohn; Ayoola Adekile; Vishal Mahabir
Journal:  J Hosp Med       Date:  2006-11       Impact factor: 2.960

5.  A meta-analysis of continuing medical education effectiveness.

Authors:  Maliheh Mansouri; Jocelyn Lockyer
Journal:  J Contin Educ Health Prof       Date:  2007       Impact factor: 1.355

6.  Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.

Authors:  Jay L Goldstein; Kimberly B Howard; Surrey M Walton; Trent P McLaughlin; Denise T Kruzikas
Journal:  Clin Gastroenterol Hepatol       Date:  2006-11       Impact factor: 11.382

Review 7.  OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines.

Authors:  W Zhang; R W Moskowitz; G Nuki; S Abramson; R D Altman; N Arden; S Bierma-Zeinstra; K D Brandt; P Croft; M Doherty; M Dougados; M Hochberg; D J Hunter; K Kwoh; L S Lohmander; P Tugwell
Journal:  Osteoarthritis Cartilage       Date:  2008-02       Impact factor: 6.576

8.  Use of physician education and computer alert to improve targeted use of gastroprotection among NSAID users.

Authors:  Gregory A Coté; John P Rice; William Bulsiewicz; John P Norvell; Keri Christensen; Anne Bobb; Michael Postelnick; Colin W Howden
Journal:  Am J Gastroenterol       Date:  2008-05       Impact factor: 10.864

Review 9.  Systematic review of the risk of enteric infection in patients taking acid suppression.

Authors:  Jennifer Leonard; John K Marshall; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2007-05-17       Impact factor: 10.864

Review 10.  Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.

Authors:  R Andrew Moore; Sheena Derry; Ceri J Phillips; Henry J McQuay
Journal:  BMC Musculoskelet Disord       Date:  2006-10-20       Impact factor: 2.362

View more
  4 in total

1.  Effect of a course-based intervention and effect of medical regulation on physicians' opioid prescribing.

Authors:  Meldon Kahan; Tara Gomes; David N Juurlink; Michael Manno; Lynn Wilson; Angela Mailis-Gagnon; Anita Srivastava; Rhoda Reardon; Irfan A Dhalla; Muhammad M Mamdani
Journal:  Can Fam Physician       Date:  2013-05       Impact factor: 3.275

2.  Attitude and Knowledge of Indian Emergency Care Residents towards Use of Proton Pump Inhibitors.

Authors:  Biswa Mohan Padhy; Hemant Singh Bhadauria; Yogendra Kumar Gupta
Journal:  Int Sch Res Notices       Date:  2014-11-19

3.  Development of a multicomponent implementation strategy to reduce upper gastrointestinal bleeding risk in patients using warfarin and antiplatelet therapy, and protocol for a pragmatic multilevel randomized factorial pilot implementation trial.

Authors:  Jacob E Kurlander; Danielle Helminski; Michael Lanham; Jennifer L Henstock; Kelley M Kidwell; Sarah L Krein; Sameer D Saini; Caroline R Richardson; Raymond De Vries; Kenneth Resnicow; Allison Laboon Ruff; David M Wallace; Elizabeth K Jones; Linda K Perry; Jacqueline Parsons; Nghi Ha; Tina Alexandris-Souphis; Dale Dedrick; Elizabeth Aldridge; Geoffrey D Barnes
Journal:  Implement Sci Commun       Date:  2022-01-28

4.  Evaluation of the community pharmacists' performance in the screening of non-steroidal anti-inflmmatory drugs risks in Saudi Arabia.

Authors:  Azizah M Malebari; Ahdab N Khayyat; Ruba A Mahdali; Jumana S Alamoudi; Bushra Y Alsayed; Samar A Alrasheed
Journal:  Saudi Med J       Date:  2020-08       Impact factor: 1.484

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.